A bifurcation Stent, which is more difficult to cure, is a blockage at the point where the blood vessel splits in two. The blood vessel’s two branches are becoming smaller. There is a danger that the other branch will close if a balloon angioplasty is done in one. Usually, just one or two stents are inserted, and there is a probability that the side branch will have recurrence.
The blockage can be removed using a brand-new Nile Pax stent that has been particularly created. Stent, which is drug-coated and covers both branches of the artery, makes it easier to reach both branches of the artery for potential future therapy. Additionally, less dye is utilised, and the process takes much less time.
The Global Bifurcation Stent market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2023 to 2030.
The market has been divided into coronary vascular and peripheral vascular segments based on the application. Due to the availability of specific solutions for coronary bifurcation lesions, increased awareness, and an increase in the quantity of percutaneous coronary intervention operations, the coronary vascular segment held the biggest proportion of the market.
Due to continuing clinical trials and investments by market participants, the coronary vascular segment is anticipated to maintain its leadership during the forecasted period. This will probably lead to the launch of new products and expand the uses of current ones for bifurcation lesions.
The market segment expected to grow the fastest throughout the projection period is peripheral vascular. This is due to increased public knowledge of peripheral arterial diseases (PAD) and their increasing prevalence. Because it is challenging to deploy stents in smaller peripheral arteries, they cannot be utilised to treat PAD.
Angioplasty is hence the preferred method of treatment. For the treatment of bifurcation lesions, stent implantation is typically chosen over balloon angioplasty.
© Copyright 2017-2023. Mobility Foresights. All Rights Reserved.